Luckily, a vast range of skilled and dedicated patient advocates can provide support to people with cancer and their loved ones. They raise funds and awareness, build programs and communities, share ...

The Food and Drug Administration this month approved Optune Pax, from Novocure—a wearable tumor-treating fields (TTFields) device that uses electric fields to kill cancer cells—for the treatment of ...

“I was diagnosed with prostate cancer in 2007, and early detection saved my life,” said Arians, a former Super Bowl–winning head coach and prostate cancer survivor, in the Novartis press release. “I ...

Treating advanced gastric or gastroesophageal junction cancer with Keytruda (pembrolizumab) is associated with similar overall survival time compared with chemotherapy in people with PD-L1–positive ...

After adjusting for several factors, they determined that areas with increased precipitation had a higher incidence of all cancers; they also noted that climate zone also significantly affected cancer ...

Zoldonrasib is a novel RAS (ON) tri-complex inhibitor that selectively targets the G12D mutation. Unlike currently approved KRAS G12C-targeted therapies, which lock mutated KRAS in an inactive ...

“The FDA approval of the first menin inhibitor is a major breakthrough for patients with relapsed or refractory acute leukemia with a KMT2A translocation, a genetic alteration associated with a very ...

Known for “Schitt’s Creek,” “Home Alone” and “Beetlejuice,” Catherine O’Hara died of a pulmonary embolism (a blood clot in the lungs) caused by rectal cancer.

Our fourth annual Cancer Health 25 honors individuals working tirelessly to define and address such disparities. They include doctors, nurses, researchers, volunteers, patient navigators, grassroots ...

The global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in ...

“The goal of this study is not to divert funds away from cancers that are well supported, but rather expand funding for other cancers that aren’t getting enough support currently,” lead author Suneel ...